Risk factors
Cardiff Oncology (CRDF) risk factors
Item 1A of every Cardiff Oncology, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors63 risks6 new2 dropped7 reworded
Cardiff Oncology faces growing financial strain with an auditor going concern warning and accumulated deficit rising to $430.0 million.
Filed Feb 24, 2026 - FY2024 10-K risk factors59 risks
Cardiff Oncology is a clinical-stage biotech focused on its sole product candidate, onvansertib, which requires substantial additional capital to develop.
Filed Feb 27, 2025